People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Her copay for Zepbound has been around $10 per month since she started the drug in March. Skala said she has lost 52 pounds and noticed "profound improvements" in her mental health, sleep and ...

Cheaper compounded drugs are still being sold Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs ...

Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1 time each week, at any time of the day.

Zepbound will be excluded. It's important to have a range of drugs to treat a disease as widespread as obesity in the U.S., said Dr. Angela Fitch, chief medical officer of knownwell, an obesity ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.